Is Telix Pharmaceuticals Ltd (TLX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 18.3% / 30% | 5.6% / 30% | 5.4% / 30% | 0.72% / 5% | ✓ HALAL |
| DJIM | 18.3% / 33% | 5.6% / 33% | 5.4% / 33% | 0.72% / 5% | ✓ HALAL |
| MSCI | 40.1% / 33% | 12.2% / 33% | 11.9% / 33% | 0.72% / 5% | ✗ NOT HALAL |
| S&P | 18.3% / 33% | 5.6% / 33% | 5.4% / 33% | 0.72% / 5% | ✓ HALAL |
| FTSE | 40.1% / 33% | 12.2% / 33% | 11.9% / 50% | 0.72% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 47.5% | |
| Operating Margin | 1.9% | |
| Net Margin | -0.9% | |
| Return on Equity (ROE) | -1.9% | |
| Return on Assets (ROA) | 1.1% |
Cash Flow & Balance Sheet
| Free Cash Flow | -$61M |
| Total Debt | $467M |
| Debt-to-Equity | 112.5 |
| Current Ratio | 1.4 |
| Total Assets | $1.2B |
Price & Trading
| Last Close | $8.97 |
| 50-Day MA | $7.56 |
| 200-Day MA | $10.31 |
| Avg Volume | 246K |
| Beta | 1.1 |
|
52-Week Range
$6.28
| |
About Telix Pharmaceuticals Ltd (TLX)
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Purification Calculator
As a halal stock with 0.72% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Telix Pharmaceuticals Ltd (TLX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Telix Pharmaceuticals Ltd is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Telix Pharmaceuticals Ltd's debt ratio?
Telix Pharmaceuticals Ltd's debt ratio is 18.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 40.1%.
Does Telix Pharmaceuticals Ltd require dividend purification?
Yes, Telix Pharmaceuticals Ltd has an impermissible income ratio of 0.72%, which means 0.72% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Telix Pharmaceuticals Ltd's key financial metrics?
Telix Pharmaceuticals Ltd has a market capitalization of $3.1B, and revenue of $804M. The company maintains a gross margin of 47.5% and a net margin of -0.9%. Return on equity stands at -1.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.